Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | CTSC | P53634 | 11/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920509 | 1.00 | MME (0.45) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL18920557 | 0.85 | CTSC (0.44) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL21144620 | 0.85 | CTSC (0.44) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL23357210 | 0.84 | MAPK1 (0.47) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL18920691 | 0.84 | MAPK1 (0.47) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL21144850 | 0.84 | MAPK1 (0.47) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL18920545 | 0.83 | MME (0.46) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL21144938 | 0.83 | MME (0.46) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL21144923 | 0.82 | MME (0.45) | MMECTSCKCNH2MMP12MMP13 | |
| SCHEMBL21144709 | 0.82 | MAOB (0.43) | MMECTSCKCNH2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | MME 4530/4885CTSC 3793/4885KCNH2 2927/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | MME 4530/4885CTSC 3793/4885KCNH2 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.